Lila’s Nvidia-backed raise is about more than money. It is an attempt to industrialise discovery—and to sell it as capacity to pharma, chipmakers and energy groups.
On 14 October, Lila Sciences said it had added $115mn to its Series A, bringing the round to $350mn, total capital raised to roughly $550mn and its valuation to more than $1.3bn. Nvidia’s venture arm joined the extension. Lila also disclosed a plan to commercialise its platform beyond life sciences and to build out a newly leased 235,500-square-foot site in Cambridge, Massachusetts.
Those are eye-catching numbers.
